HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA.

doi:10.1186/s13075-021-02607-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA.

Arthritis research & therapy - 18 Sept 2021

Rigby William, Buckner Jane H, Louis Bridges S, Nys Marleen, Gao Sheng, Polinsky Martin, Ray Neelanjana, Bykerk Vivian

Abstract excerpt

BACKGROUND: Certain risk alleles associated with autoantibody-positive rheumatoid arthritis (RA) have been linked to poorer prognoses. In patients with autoantibody-positive RA, abatacept shows differential efficacy to tumor necrosis factor inhibitors. Our aim was to investigate the relationship between clinical response to abatacept and to adalimumab and presence of risk alleles encoding human leukocyte antigen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Abatacept
Share to Adalimumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alleles

Share to Antirheumatic Agents

Share to Arthritis, Rheumatoid

Share to HLA-DRB1 Chains

Share to Rheumatoid Arthritis Research and Therapies

Share to Single-Blind Method

Source

Open in PubMed Open full text

Identifiers

PMID: 34537057
DOI: 10.1186/s13075-021-02607-7
PMCID: PMC8449494

Provenance

PubMed metadata and Literature Corpus relationships.